SynthesisLancet (London, England)2022

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Gerhardt Attard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.